Pharmaceutical Technology18d
GXV-001 by GEXVal for Rett Syndrome: Likelihood of Approval
GXV-001 is under clinical development by GEXVal and currently in Phase I for Rett Syndrome. According to GlobalData, Phase I drugs for Rett Syndrome does not have sufficient historical data to build ...
Pharmaceutical Technology18d
FOG-001 by Fog Pharmaceuticals for Solid Tumor: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate ...
PipelineReview.com1mon
Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting
In the poster, entitled “EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment”. Egle scientists present evidence that EGL-001, ...
Business Wire1mon
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD). Data from 10 ...
Toronto3y
Open Calls for Affordable Housing Initiatives
Every year, the City of Toronto issues Requests for Proposals (RFPs) to support its goal of achieving or exceeding the provincial housing target of 285,000 new Toronto homes and the City’s target of ...